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Background:  Patients with coronary artery disease need live-long medical treatment with multiple agents for secondary prevention. Little 
is known about the compliance to long-term secondary prevention treatment of stable coronary artery disease (CAD) in clinical practice.
methods:  Between Sept 2001 and March 2003, a total of 2,002 consecutive patients with angina pectoris and first angiographic diagnosis 
of CAD were enrolled in the STAR-Registry (50 centres). We examined the compliance to guideline recommended medical treatment over 
a 5-year-follow-up in stable CAD in clinical practice in Germany, separated by gender.
results:  Current practice guidelines recommend long-term treatment with aspirin, ACE-inhibitors and statins for patients with stable 
coronary artery disease. The use of these drugs was high in both females and males but declined over the time of 5 years of follow up after 
the first angiographic diagnosis of CAD. The decline in aspirin treatment might be partly compensated by an increase in the use of Vit-K-
antagonists probably due to a higher rate of atrial fibrillation over time. We found an increase in the use of calcium-blockers which might be 
seen as an aggravation of anti-anginal treatment over time.
Conclusion:  Five years after the first angiographic diagnosis of CAD only 77% of patients stayed on aspirin, 50% on ACE-inhibitors and 
67% on statins. There is need for improvement towards better long-term compliance to guideline recommended drug treatment.
Drug Females, n=600 (30%) Males, n=1402 (70%)
Baseline 1-year 5-year Baseline 1-year 5-year
Aspirin 89.3% 73.4% 75.7% 90.3% 78.8% 79.5%
Beta-blocker 77.5% 74.0% 80.0% 77.1% 71.0% 75.2%
ACE-inhibitor 61.3% 50.8% 48.9% 59.3% 52.4% 52.0%
Calcium antagonist 16.8% 18.0% 26.3% 12.7% 15.0% 19.2%
Statin 73.3% 61.0% 67.2% 73.8% 63.5% 66.8%
Vit K antagonist 4.0% 5.9% 13.7% 3.4% 5.5% 11.0%
